Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

ASGCT 2023

Epigenetic Regulation for Neurology
Viral Delivery for Neurology
Genomic Engineering Platform Evolution
Assays to Support Clinical Programs